Logo-jrip
Submitted: 04 May 2020
Accepted: 17 Jul 2020
ePublished: 28 Jul 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2020;9(4): e32.
doi: 10.34172/jrip.2020.32
  Abstract View: 169
  PDF Download: 100

Original

The protective effect of lycopene supplement against vancomycin-induced nephrotoxicity; a randomized double-blind placebo-controlled clinical trial

Somayeh Haghighipour 1 ORCID logo, Rasool Soltani 2 ORCID logo, Ali Anjomshoa 3 * ORCID logo

1 Infectious Disease and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding author: Ali Anjomshoa, Email: Dr.AliAnjomshoa@gmail.com

Abstract

Introduction: It has been proposed that oxidative stress plays a crucial role in vancomycin-induced nephrotoxicity (VIN).

Objectives: The present study aimed to investigate the nephroprotective effects of lycopene, as a powerful antioxidant, on VIN.

Patients and Methods: In the present study, individuals who received vancomycin (VCM) for any indication were assigned to drug (n=28) and control (n=30) groups. The individuals in the drug group received 25 mg of oral lycopene daily for 10 days started concurrently with VCM and the patients in the placebo group received placebo tablets with VCM. Serum levels of creatinine (SCr) and blood urea nitrogen (BUN) as well as creatinine clearance (CrCl) were determined and recorded before the start of interventions, every other day during therapy, and 12 hours after the last dose of VCM in 10th day of treatment for all participants. Finally, the mean values of the measured parameters were compared between the groups.

Results: The mean values of SCr were significantly lower in drug group compared to placebo at the 4th (0.85 ± 0.18 vs. 0.98 ± 0.22, P=0.016) and 6th (0.83 ± 0.18 vs. 0.95 ± 0.21, P=0.029) days. Also, CrCl was significantly higher in the drug group at the 4th day compared to placebo (105.82 ± 20.09 vs. 94.67 ± 20.53, P=0.041). Regarding VCM-induced AKI, no case was reported in any group.

Conclusion: Lycopene has the potential for diminution of VCM-induced nephrotoxicity (VIN). However, more investigations with larger sample size are necessary to confirm this effect.

Keywords: Vancomycin, Nephrotoxicity, Lycopene

Implication for health policy/practice/research/medical education:

It has been proposed that oxidative stress plays a crucial role in vancomycin-induced nephrotoxicity (VIN). The present study aimed to investigate the nephroprotective effects of lycopene, as a powerful antioxidant, on VIN. Lycopene has the potential for reduction of VIN. However, more investigations with larger sample size are necessary to confirm this effect.

Please cite this paper as: Haghighipour S, Soltani R, Anjomshoa A. The protective effect of lycopene supplement against vancomycin-induced nephrotoxicity; a randomized double-blind placebo-controlled clinical trial. J Renal Inj Prev. 2020; 9(4): e32. doi: 10.34172/jrip.2020.32.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 169

Your browser does not support the canvas element.


PDF Download: 100

Your browser does not support the canvas element.